The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
Open accessAbstract
Purpose: To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS). Patients and Methods: We compared the long-term outcome of patients with MDS treated with EPO plus G-CSF (n = 121) with untreated patients (n = 237) with MDS using multivariate Cox regression with delayed entry, for the first time adjusting for all major prognostic variables (WHO classification, karyotype, cytopenias, level of transfusion-need, age, and sex). Results: The erythroid response rate to EPO plus G-CSF was 39%, and the median response duration 23 months (range, 3 to 116+). In the multivariate analysis, treatment was associated with improved overall survival (hazard ratio, 0.61; 95% CI, 0.44 to 0.83; P = .002). Interestingly, this positive association was primarily observed in patients requiring fewer than 2 units of RBCs per month. Treatment was not linked to the rate of acute myeloid leukemia in any defined subgroup, including patients with an increase of marrow blasts or an unfavorable karyotype. Conclusion: The inherent risk of leukemic evolution in MDS makes the current investigation highly relevant, in light of the recent reports of potential negative effects of EPO treatment on outcome in patients with cancer. We conclude that treatment of anemia in MDS with EPO plus G-CSF may have a positive impact on outcome in patients with no or low transfusion need, while not affecting the risk of leukemic transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
- Statistical Models for Epidemiology
(2013) · Bayesian Methods in Epidemiology · doi:10.1201/b15382-9 · Cited by 1,346
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,032
Self-citationBlood Transfusion in Elderly Patients with Acute Myocardial Infarction
Wu, W.-C., Rathore, S. S., Wang, Y., Radford, M. J., & Krumholz, H. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010615 · Cited by 952
Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 865
Self-citationLeyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.150 · Cited by 668
Cited by
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Foran, J. M., Gaensler, K., Garcia-Manero, G., Gore, S. D., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0005 · Cited by 290
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“European hematologists have provided pivotal contributions to developing effective treatments for MDS, including erythropoietin and azacitidine.(126,137) Recommendations for treatment of the individual patient with MDS have also been developed.”
BackgroundRisk and timing of cardiovascular death among patients with myelodysplastic syndromes
Brunner, A. M., Blonquist, T. M., Hobbs, G. S., Amrein, P. C., Neuberg, D. S., Steensma, D. P., Abel, G. A., & Fathi, A. T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010165 · Cited by 63
Anemia as the Main Manifestation of Myelodysplastic Syndromes
Santini, V. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.06.002 · Cited by 52
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
de Swart, L., Reiniers, C., Bagguley, T., van Marrewijk, C., Bowen, D., Hellström-Lindberg, E., Tatic, A., Symeonidis, A., Huls, G., Cermak, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.171884 · Cited by 48
Self-citation
Metadata
- Authors
- Jädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-20
- Volume
- 26
- Issue
- 21
- Pages
- 3607-3613
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165036959
- Cited by
- 300
- References
- 42
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome. https://app.cochat.ai/papers/10.1200/jco.2007.15.4906
- The paper
- Jädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E. (2008). Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.4906
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
